The best train for the south Acid, the pH-POA itself, which is not absorbed by the intestine. POA inhalation as Erg nzung given to PZA Oral h tte following benefits: You would the size e of the bacterial population of PZA orally and the duration of the period of the T least, get tet to hen increased because the fragment active and would probably not be the first cause 3-Methyladenine 3-MA of Lebertoxizit going t be, it w re a reduction of the oral dose PZA Hepatotoxizit t erm too aligned and thus for almost all the resistance mutations were found in the pncA gene, encoding the deamination original, k they nnte bactericidal activity of t, even in the presence of PZA resistance. A combination of oral treatment with a high dose of rifamycins, oral PZA, hopefully, TMC diarylquinolone and inhalation therapy assistant POA M for may have can k A huge reduction in the duration to make the treatment of tuberculosis.
We pulmonary think it is realistic to expect that such a combination of drugs k Nnte the duration of treatment in a single month reduced. Chrysin 480-40-0 . Pulmonary delivery of anti-tuberculosis drugs delivery of targeted therapies against tuberculosis infected lungs directly results in immediate contact with the drug TB bacteria, which leads to high doses of local drug and the rapid onset of the T Th stock. The lung has a big s surface And surface adsorption of a thin alveolar epithelium. H Here lung bioavailability and rapid absorption of the drug through the lung epithelium erm Adjusted lower doses of drugs, while maintaining an effective systemic concentration.
Should have a lower dose with the absence of first pass metabolism and the prevention of gastrointestinal dinner combined input possibility, a reduction of systemic side effects and improved reps. A number of anti-TB drugs have been in dry microparticles for pulmonary delivery, including normal capreomycin and para-Aminosalicyls Acid has been formulated. Pimobendan The results showed that the direct supply leads to the lungs indeed to high local concentrations and reduced bacterial load in the same treatment by other means made available, providing the M Possibility, h get Higher doses and fewer systemic side effects . TB drugs have been also formulated in nanoparticles for pulmonary delivery by a number of researchers.
e encapsulation of drugs in nanoparticles, the M Opportunity, stability t, and better protection of the molecule of interest, drug action and delayed Siege to release , improving the bioavailability of poorly l soluble therapeutic and drug targeting to specific organs, cells or receptors. It also allows the small size E of the nanoparticles to escape them two mechanisms and phagocytic mukozili Re clearance in the lungs and Pandey al. administered rifampicin, isoniazid and pyrazinamide encapsulated in biodegradable polylactide co-glycolide nanoparticles in the lungs of guinea pigs with nebulization. They showed that the aerosol formulation to maintain therapeutic concentrations in the lungs until today. In an improved drug formulations, PLG, Sharma et al. Surface Surface functionalized nanoparticles with wheat germ agglutinin, a lectin withbioadhesive properties, which also sustained levels of drug in the lungs of guinea pigs to this day. Zahoor et al. shown that alginate nanoparticles encapsulating rifampic